Positive results Phase 1b trial in sarcopenia
Primary and secondary endpoints have been met in this placebo-controlled study in disuse-induced muscle atrophy. RJx-01 was safe and well tolerated and the innovative formulation confirmed excellent pharmacokinetics.
Publication of animal data on RJx-01
Data published in JCI Insight show that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models.
Advisory Board endorses clinical Ph 2b strategy
Rejuvenate Biomed organized a Clinical Advisory Board meeting to discuss the clinical development of lead candidate RJx-01 in sarcopenia.
Groundbreaking clinical trial started
The first clinical trial with RJx-01 has started in disuse-induced muscle atrophy, marking Rejuvenate Biomed’s maturation to a clinical-stage company.
€15.7 million Series B round secured
This round was led by Rejuveron Life Sciences and Vesalius Biocapital. The funding is being used to accelerate the clinical development of RJx-01.